O	0	15	Thrombospondins	Thrombospondin	NNS	B-NP
O	15	16	,	,	,	O
O	17	24	metallo	metallo	NN	B-NP
O	25	34	proteases	protease	NNS	I-NP
O	35	38	and	and	CC	O
O	39	53	thrombospondin	thrombospondin	NN	B-NP
O	54	63	receptors	receptor	NNS	I-NP
O	64	73	messenger	messenger	NN	I-NP
O	74	77	RNA	RNA	NN	I-NP
O	78	81	and	and	CC	O
O	82	89	protein	protein	NN	B-NP
O	90	100	expression	expression	NN	I-NP
O	101	103	in	in	IN	B-PP
O	104	113	different	different	JJ	B-NP
B-Cancer	114	120	tumour	tumour	NN	I-NP
I-Cancer	121	129	sublines	subline	NNS	I-NP
O	130	132	of	of	IN	B-PP
O	133	136	the	the	DT	B-NP
B-Cancer	137	144	Dunning	Dunning	JJ	I-NP
I-Cancer	145	153	prostate	prostate	NN	I-NP
I-Cancer	154	160	cancer	cancer	NN	I-NP
O	161	166	model	model	NN	I-NP
O	166	167	.	.	.	O

O	168	182	Thrombospondin	Thrombospondin	NN	B-NP
O	183	185	is	be	VBZ	B-VP
O	186	187	a	a	DT	B-NP
O	188	194	potent	potent	JJ	I-NP
O	195	204	inhibitor	inhibitor	NN	I-NP
O	205	207	of	of	IN	B-PP
O	208	220	angiogenesis	angiogenesis	NN	B-NP
O	221	224	and	and	CC	O
O	225	230	might	might	MD	B-VP
O	231	240	therefore	therefore	RB	I-VP
O	241	243	be	be	VB	I-VP
O	244	253	important	important	JJ	B-ADJP
O	254	256	in	in	IN	B-PP
O	257	268	controlling	control	VBG	B-VP
B-Cancer	269	275	tumour	tumour	NN	B-NP
O	276	282	growth	growth	NN	I-NP
O	282	283	.	.	.	O

O	284	287	TSP	TSP	NN	B-NP
O	288	297	interacts	interact	VBZ	B-VP
O	298	302	with	with	IN	B-PP
O	303	304	a	a	DT	B-NP
O	305	311	number	number	NN	I-NP
O	312	314	of	of	IN	B-PP
O	315	324	proteases	protease	NNS	B-NP
O	325	328	and	and	CC	I-NP
O	329	338	receptors	receptor	NNS	I-NP
O	339	342	and	and	CC	B-PP
O	343	345	in	in	IN	B-PP
O	346	350	this	this	DT	B-NP
O	351	354	way	way	NN	I-NP
O	355	363	inhibits	inhibit	VBZ	B-VP
O	364	375	stimulation	stimulation	NN	B-NP
O	376	378	of	of	IN	B-PP
O	379	391	angiogenesis	angiogenesis	NN	B-NP
O	391	392	.	.	.	O

O	393	395	An	An	DT	B-NP
O	396	403	earlier	early	JJR	I-NP
O	404	409	study	study	NN	I-NP
O	410	416	showed	show	VBD	B-VP
O	417	421	that	that	IN	B-SBAR
O	422	436	thrombospondin	thrombospondin	NN	B-NP
O	437	439	is	be	VBZ	B-VP
O	440	449	expressed	express	VBN	I-VP
O	450	452	in	in	IN	B-PP
B-Pathological_formation	453	459	benign	benign	JJ	B-NP
I-Pathological_formation	460	469	prostatic	prostatic	JJ	I-NP
I-Pathological_formation	470	481	hyperplasia	hyperplasia	NN	I-NP
O	482	483	(	(	(	O
B-Pathological_formation	483	486	BPH	BPH	NN	B-NP
O	486	487	)	)	)	O
O	488	491	and	and	CC	O
B-Pathological_formation	492	496	high	high	JJ	B-NP
I-Pathological_formation	496	497	-	-	HYPH	I-NP
I-Pathological_formation	497	502	grade	grade	NN	I-NP
I-Pathological_formation	503	512	prostatic	prostatic	JJ	I-NP
I-Pathological_formation	513	528	intraepithelial	intraepithelial	JJ	I-NP
I-Pathological_formation	529	538	neoplasia	neoplasia	NN	I-NP
O	539	540	(	(	(	O
B-Pathological_formation	540	543	PIN	PIN	NN	B-NP
O	543	544	)	)	)	O
O	545	548	but	but	CC	O
O	549	551	is	be	VBZ	B-VP
O	552	558	absent	absent	JJ	B-ADJP
O	559	561	in	in	IN	B-PP
B-Cancer	562	570	prostate	prostate	NN	B-NP
I-Cancer	571	577	cancer	cancer	NN	I-NP
O	577	578	.	.	.	O

O	579	582	The	The	DT	B-NP
O	583	590	present	present	JJ	I-NP
O	591	596	study	study	NN	I-NP
O	597	600	was	be	VBD	B-VP
O	601	610	therefore	therefore	RB	I-VP
O	611	619	designed	design	VBN	I-VP
O	620	622	to	to	TO	I-VP
O	623	631	evaluate	evaluate	VB	I-VP
O	632	635	the	the	DT	B-NP
O	636	646	expression	expression	NN	I-NP
O	647	649	of	of	IN	B-PP
O	650	664	thrombospondin	thrombospondin	NN	B-NP
O	665	666	1	1	CD	I-NP
O	667	670	and	and	CC	I-NP
O	671	672	2	2	CD	I-NP
O	673	674	(	(	(	O
O	674	677	TSP	TSP	NN	B-NP
O	677	678	-	-	HYPH	B-NP
O	678	679	1	1	CD	I-NP
O	679	680	,	,	,	O
O	681	684	TSP	TSP	NN	B-NP
O	684	685	-	-	HYPH	O
O	685	686	2	2	CD	B-NP
O	686	687	)	)	)	O
O	687	688	,	,	,	O
O	689	692	TSP	TSP	NN	B-NP
O	693	702	receptors	receptor	NNS	I-NP
O	703	707	CD36	CD36	NN	I-NP
O	708	711	and	and	CC	I-NP
O	712	716	CD47	CD47	NN	I-NP
O	716	717	,	,	,	O
O	718	721	and	and	CC	O
O	722	728	matrix	matrix	NN	B-NP
O	728	729	-	-	HYPH	I-NP
O	729	745	metalloproteases	metalloproteas	NNS	I-NP
O	746	747	2	2	CD	I-NP
O	748	751	and	and	CC	I-NP
O	752	753	9	9	CD	I-NP
O	754	755	(	(	(	O
O	755	758	MMP	MMP	NN	B-NP
O	758	759	-	-	HYPH	B-ADJP
O	759	760	,	,	,	O
O	761	764	MMP	MMP	NN	B-NP
O	764	765	-	-	HYPH	B-NP
O	765	766	9	9	CD	I-NP
O	766	767	)	)	)	O
O	768	770	in	in	IN	B-PP
O	771	772	a	a	DT	B-NP
O	773	776	rat	rat	NN	I-NP
B-Cancer	777	785	prostate	prostate	NN	I-NP
I-Cancer	786	792	cancer	cancer	NN	I-NP
O	793	798	model	model	NN	I-NP
O	798	799	.	.	.	O

O	800	802	By	By	IN	B-PP
O	803	808	using	use	VBG	B-VP
O	809	829	immunohistochemistry	immunohistochemistry	NN	B-NP
O	829	830	,	,	,	O
O	831	838	Western	Western	NN	B-NP
O	839	843	blot	blot	NN	I-NP
O	843	844	,	,	,	O
O	845	848	and	and	CC	O
O	849	853	real	real	JJ	B-NP
O	853	854	-	-	HYPH	I-NP
O	854	858	time	time	NN	I-NP
O	859	862	PCR	PCR	NN	I-NP
O	863	866	the	the	DT	B-NP
O	867	877	expression	expression	NN	I-NP
O	878	886	patterns	pattern	NNS	I-NP
O	887	889	of	of	IN	B-PP
O	890	893	TSP	TSP	NN	B-NP
O	893	894	-	-	HYPH	B-NP
O	894	895	1	1	CD	I-NP
O	895	896	,	,	,	O
O	897	900	TSP	TSP	NN	B-NP
O	900	901	-	-	HYPH	O
O	901	902	2	2	CD	B-NP
O	902	903	,	,	,	O
O	904	908	CD36	CD36	NN	B-NP
O	908	909	,	,	,	O
O	910	914	CD47	CD47	NN	B-NP
O	914	915	,	,	,	O
O	916	919	MMP	MMP	NN	B-NP
O	919	920	-	-	HYPH	O
O	920	921	2	2	CD	B-NP
O	921	922	,	,	,	O
O	923	926	and	and	CC	O
O	927	930	MMP	MMP	NN	B-NP
O	930	931	-	-	HYPH	B-NP
O	931	932	9	9	CD	I-NP
O	933	937	were	be	VBD	B-VP
O	938	950	investigated	investigate	VBN	I-VP
O	951	953	in	in	IN	B-PP
O	954	960	normal	normal	JJ	B-NP
O	961	964	rat	rat	NN	I-NP
B-Tissue	965	973	prostate	prostate	NN	I-NP
I-Tissue	974	980	tissue	tissue	NN	I-NP
O	981	984	and	and	CC	O
O	985	989	five	five	CD	B-NP
B-Tissue	990	999	malignant	malignant	JJ	I-NP
I-Tissue	1000	1007	Dunning	Dunning	JJ	I-NP
I-Tissue	1008	1016	sublines	subline	NNS	I-NP
I-Tissue	1017	1023	tissue	tissue	NN	I-NP
O	1023	1024	.	.	.	O

O	1025	1028	TSP	TSP	NN	B-NP
O	1028	1029	-	-	HYPH	B-NP
O	1029	1030	1	1	CD	I-NP
O	1031	1035	mRNA	mRNA	NN	I-NP
O	1036	1042	levels	level	NNS	I-NP
O	1043	1047	were	be	VBD	B-VP
O	1048	1057	decreased	decrease	VBN	I-VP
O	1058	1060	in	in	IN	B-PP
O	1061	1064	all	all	DT	B-NP
B-Cancer	1065	1072	tumours	tumour	NNS	I-NP
O	1073	1081	compared	compare	VBN	B-PP
O	1082	1086	with	with	IN	B-PP
O	1087	1093	normal	normal	JJ	B-NP
B-Organ	1094	1102	prostate	prostate	NN	I-NP
O	1102	1103	.	.	.	O

O	1104	1111	However	However	RB	B-ADVP
O	1111	1112	,	,	,	O
O	1113	1118	there	there	EX	B-NP
O	1119	1122	was	be	VBD	B-VP
O	1123	1125	no	no	DT	B-NP
O	1126	1136	difference	difference	NN	I-NP
O	1137	1139	in	in	IN	B-PP
O	1140	1150	expression	expression	NN	B-NP
O	1151	1153	of	of	IN	B-PP
O	1154	1157	TSP	TSP	NN	B-NP
O	1157	1158	-	-	HYPH	B-NP
O	1158	1159	2	2	CD	I-NP
O	1160	1163	and	and	CC	O
O	1164	1168	CD36	CD36	NN	B-NP
O	1169	1173	mRNA	mRNA	NN	I-NP
O	1174	1176	in	in	IN	B-PP
O	1177	1182	these	these	DT	B-NP
B-Tissue	1183	1190	samples	sample	NNS	I-NP
O	1190	1191	.	.	.	O

O	1192	1195	MMP	MMP	NN	B-NP
O	1195	1196	-	-	HYPH	O
O	1196	1197	2	2	CD	B-NP
O	1198	1201	was	be	VBD	B-VP
O	1202	1211	increased	increase	VBN	I-VP
O	1212	1216	with	with	IN	B-PP
O	1217	1227	malignancy	malignancy	NN	B-NP
O	1227	1228	,	,	,	O
O	1229	1232	but	but	CC	O
O	1233	1235	no	no	DT	B-NP
O	1236	1246	expression	expression	NN	I-NP
O	1247	1249	of	of	IN	B-PP
O	1250	1253	MMP	MMP	NN	B-NP
O	1253	1254	-	-	HYPH	B-NP
O	1254	1255	9	9	CD	I-NP
O	1256	1259	was	be	VBD	B-VP
O	1260	1264	seen	see	VBN	I-VP
O	1264	1265	.	.	.	O

O	1266	1269	The	The	DT	B-NP
O	1270	1274	CD47	CD47	NN	I-NP
O	1275	1283	receptor	receptor	NN	I-NP
O	1284	1287	did	do	VBD	B-VP
O	1288	1296	slightly	slightly	RB	I-VP
O	1297	1305	increase	increase	VB	I-VP
O	1306	1310	with	with	IN	B-PP
O	1311	1321	malignancy	malignancy	NN	B-NP
O	1322	1328	except	except	IN	B-PP
O	1329	1332	for	for	IN	B-PP
B-Cancer	1333	1338	H3327	H3327	NN	B-NP
O	1338	1339	.	.	.	O

O	1340	1343	The	The	DT	B-NP
O	1344	1351	results	result	NNS	I-NP
O	1352	1358	showed	show	VBD	B-VP
O	1359	1363	that	that	IN	B-SBAR
O	1364	1378	thrombospondin	thrombospondin	NN	B-NP
O	1379	1381	is	be	VBZ	B-VP
O	1382	1391	expressed	express	VBN	I-VP
O	1392	1394	in	in	IN	B-PP
O	1395	1401	normal	normal	JJ	B-NP
B-Organ	1402	1410	prostate	prostate	NN	I-NP
O	1411	1414	but	but	CC	B-PP
O	1415	1418	not	not	RB	B-PP
O	1419	1421	in	in	IN	I-PP
B-Cancer	1422	1430	prostate	prostate	NN	B-NP
I-Cancer	1431	1438	tumours	tumour	NNS	I-NP
O	1439	1441	in	in	IN	B-PP
O	1442	1443	a	a	DT	B-NP
O	1444	1447	rat	rat	NN	I-NP
O	1448	1453	model	model	NN	I-NP
O	1453	1454	.	.	.	O

O	1455	1469	Simultaneously	Simultaneously	RB	B-ADVP
O	1469	1470	,	,	,	O
O	1471	1474	MMP	MMP	NN	B-NP
O	1474	1475	-	-	HYPH	O
O	1475	1476	2	2	CD	B-NP
O	1477	1487	expression	expression	NN	I-NP
O	1488	1497	increases	increase	VBZ	B-VP
O	1498	1502	with	with	IN	B-PP
O	1503	1513	malignancy	malignancy	NN	B-NP
O	1513	1514	.	.	.	O

